miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance

Eva-Maria Bogner1 | Adrian F. Daly2 | Sebastian Gulde1 | Auli Karhu3 | Martin Irmler4 | Johannes Beckers4,5,6 | Hermine Mohr1 | Albert Beckers2 | Natalia S. Pellegata1

Correspondence
Natalia S. Pellegata, Institute for Diabetes and Cancer, Helmholtz Zentrum München, Ingolstädter Landstrasse 1, 85764 Neuherberg, Germany. Email: natalia.pellegata@helmholtz-muenchen.de

Abstract
Pituitary adenomas (PAs) are intracranial tumors associated with significant morbidity due to hormonal dysregulation, mass effects and have a heavy treatment burden. Growth hormone (GH)-secreting PAs (somatotropinomas) cause acromegaly-gigantism. Genetic forms of somatotropinomas due to germline AIP mutations (AIPmut+) have an early onset and are aggressive and resistant to treatment with somatostatin analogs (SSAs), including octreotide. The molecular underpinnings of these clinical features remain unclear. We investigated the role of miRNA dysregulation in AIPmut+ vs AIPmut− PA samples by array analysis. miR-34a and miR-145 were highly expressed in AIPmut+ vs AIPmut− somatotropinomas. Ectopic expression of AIPmut (p.R271W) in Aip−/− mouse embryonic fibroblasts (MEFs) upregulated miR-34a and miR-145, establishing a causal link between AIPmut and miRNA expression. In PA cells (GH3), miR-34a overexpression promoted proliferation, clonogenicity, migration and suppressed apoptosis, whereas miR-145 moderately affected proliferation and apoptosis. Moreover, high miR-34a expression increased intracellular cAMP, a critical mitogenic factor in PAs. Crucially, high miR-34a expression significantly blunted octreotide-mediated GH inhibition and antiproliferative effects. miR-34a directly targets Gnas2 encoding Gαi2, a G protein subunit inhibiting cAMP production. Accordingly, Gαi2 levels were significantly lower in AIPmut+ vs AIPmut− PA. Taken together, these data indicate that miR-34a plays a central role in the pathogenesis of AIPmut+ PAs.

Abbreviations: 3’UTR, 3’-untranslated region; AIP, aryl hydrocarbon receptor-interacting protein; AIPmut+, AIP mutation-positive; AIPmut−, AIP mutation-negative; AML, acute myeloid leukemia; ANOVA, analysis of variance; B2m, β2-microglobulin; cAMP, cyclic adenosine monophosphate; cDNA, complementary DNA; CHX, cycloheximide; CIL, chronic lymphocytic leukemia; CO2, carbon dioxide; Ct, threshold cycle; DMEM, Dulbecco’s Modified Eagle’s Medium; DNA, deoxyribonucleic acid; dNTP, deoxynucleoside triphosphate; DTT, dithiothreitol; ELISA, enzyme-linked immunosorbent assay; EPOX, epoxometacin; ERK1/2, extracellular signal-regulated kinases 1/2; FBS, fetal bovine serum; FC, fold change; FDR, false discovery rate; FGF, fibroblast growth factor; FIP, familial isolated pituitary adenoma; GEO, Gene Expression Omnibus; GH, growth hormone; GNAL, G-protein inhibitor alpha subunit; GO, Gene Ontology; GFP, green fluorescent protein; GFP-101, G-protein coupled receptor 101; Gαi, G protein inhibitor alpha subunit; HEK293, human embryonic kidney 293 cells; Hs, horse serum; Hsp90, heat shock protein 90; Igf-1, insulin-like growth factor 1; IHC, immunohistochemistry; IPA, Ingenuity Pathway Analysis; Magma, Mitochondria-associated granulocyte-macrophage CSF-signaling molecule; MEF, mouse embryonic fibroblasts; MEF, mouse embryonic fibroblasts; MEF, mouse embryonic fibroblasts; MEN1, multiple endocrine neoplasia type 1; MEF, multiple endocrine neoplasia type 1; MEN4, multiple endocrine neoplasia type 4; mTOR, mechanistic target of rapamycin; n.s., not significant; NFPA, nonfunctioning pituitary adenoma; Oct, octreotide; oncomiR, oncogenic miRNA; PA, pituitary adenoma; Pam16, presequence translocate-associated motor 16; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; PDE, phosphodiesterase; pen/strep, penicillin-streptomycin; pERK1/2, phosphorylated ERK1/2; PLAG1, pleomorphic adenoma gene 1; PRKCD, protein kinase Cδ; qRT-PCR, quantitative real-time PCR; RIPA, radioimmunoprecipitation assay; RNA, ribonucleic acid; RNase, ribonuclease; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SEM, standard error of the mean; SNA, somatostatin analog; SSTR, somatostatin receptor; TBP, TATA-binding protein; TIF, transformed mycosis fungoides; TPR, tetratricopeptide repeat; TPT1, translationally controlled tumor protein; TSH, thyroid-stimulating hormone; Wst-1, water-soluble tetrazolium; wt, wild-type; X-LAG, X-linked acrogigantism.

Correction added on 05 October 2020 after first online publication: Projekt Deal funding statement has been added.
1 | INTRODUCTION

Pituitary adenomas (PAs) comprise up to 15% of intracranial tumors and clinically relevant PAs occur in approximately 1:1000 of the general population. They represent a challenging health burden due to disordered hormonal function and tumor growth; PA treatments are invasive, costly and require significant expertise. PAs usually occur sporadically but about 5% of cases present as part of hereditary syndromes, like familial isolated pituitary adenomas (FIPA), multiple endocrine neoplasia type 1 and 4 (MEN1, MEN4), Carney complex, McCune-Albright syndrome and X-linked acrogigantism. Mutations of the aryl hydrocarbon receptor-interacting protein (AIP) gene (AIPmut) account for 15%-20% of FIPA kindreds and are particularly important in the pathogenesis of pediatric-onset PAs.

Germline AIPmut-associated (AIPmut+) PAs are distinctive, presenting usually as growth hormone (GH)-secreting PAs (somatotropinomas) that are significantly larger, more invasive and occur at a younger age than PAs without AIP mutations (AIPmut−). The first-line treatment for sporadic somatotropinomas is transphenoidal surgery, which controls hormone hypersecretion in only about 50% of patients. For uncontrolled or recurrent disease, medical therapy with somatostatin analogs (SSA) is used in most cases. As the response to SSA is dependent on several molecular determinants, 10%-30% of patients do not respond to this therapy and can require other therapies such as pegvisomant or radiotherapy; novel therapeutic approaches (eg, metformin and statins) are now being evaluated preclinically and in small patient cohorts (reviewed in Reference 13). AIPmut + somatotropinomas are relatively resistant to first-line medical treatment with SSA. The molecular pathways that lead to this aggressive, treatment-resistant phenotype are of great clinical relevance, but the specific pathway(s) are unclear. AIPmut+ leads to impaired interaction with phosphodiesterase-4A5 (PDE4A5), dysregulated protein kinase A (PKA) function, and disrupted regulation of the inhibitory G protein, Gα2i, which can increase cyclic adenosine monophosphate (cAMP).

Like many other human tumor types, the development of PAs can be influenced by microRNAs (miRNAs); differential miRNA expression in PAs is related to histological tumor subtypes, clinical behavior and treatment responses. Interactions between miRNAs and normal, non-mutated AIP have also been noted: miR-107 is overexpressed in somatotropinomas and binds to and represses AIP in GH3 cells in vitro. As the effects of AIPmut per se on miRNA expression in human tumors are unknown, we set out to determine the miRNA signature of AIPmut+ and AIPmut− PAs. Among the miRNAs we identified as being upregulated in AIPmut+ tissue was miR-34a. We show that miR-34a has pro-oncogenic functions in PAs, likely mediated by increased cyclic adenosine monophosphate (cAMP) signaling, and that Gα2i is a direct target of miR-34a and is differentially expressed in human PAs depending on AIPmut status. We report for the first time that miR-34a upregulation leads not only to increased cell proliferation and GH secretion in vitro, but also induces resistance to the antiproliferative and hormonal effects of the first-generation somatostatin analog, octreotide.

What’s new?

Germline mutations in the AIP gene are a significant cause of inherited intracranial pituitary adenoma (PA). AIP mutation-positive (AIPmut+) PAs are characterized by early tumor onset, aggressive tumor behavior, and resistance to somatostatin analogs (SSAs). Here, the microRNA-34a (miR-34a) was found to be upregulated in AIPmut+ PA, where it correlates with pro-oncogenic features, high cAMP levels, and impaired response to octreotide, a first-generation SSA. In vitro, miR-34a directly targeted GNAI2, the gene encoding Gα2i, an inhibitor of cAMP synthesis known to be downregulated in AIPmut+ adenomas. Together, miR-34a and Gα2i may be valuable biomarkers for therapeutic stratification of AIPmut+ patients.

2 | MATERIALS AND METHODS

2.1 | Patient samples

For the current study, a total of 42 primary PAs were collected comprising 32 somatotropinomas and 10 prolactinomas. Twenty somatotropinomas were negative for AIPmut (AIPmut−) and 12 were AIPmut+. Three prolactinomas were AIPmut+ and seven were AIPmut−.
For miRNA array analysis, 22 PAs were used (10 AIPmut− and 12 AIPmut+). Among these samples, there were 12 somatotropinomas (5 AIPmut− and 7 AIPmut+). A summary of the clinical characteristics of the patients is reported in Table 1 and a list of the clinical features, mutation status and the presence of LOH is provided in Table S1. In line with previous results, the age at diagnosis was significantly lower (Figure S1A) and the tumor size was significantly larger (Figure S1B) in AIPmut+ compared to AIPmut− patients.

2.2 | RNA extraction and processing

RNA was extracted from the patient samples with the RNeasy Mini Kit (#74104, Qiagen) and RNA concentration was determined by a Spectrophotometer NanoDrop ND-1000 (Thermo Fisher Scientific, Waltham, Massachusetts).

2.3 | DNA extraction and LOH analysis

To establish germline AIP status, DNA was isolated from peripheral blood leukocytes and AIP was sequenced under conditions described.8-10 Germline DNA was also studied for deletions in AIP using multiplex ligand-dependent probe amplification (MLPA), but no germline deletions were present. DNA was also extracted following microdissection of FFPE tissue sections of pituitary adenomas and evidence of allelic loss to demonstrate loss of heterozygosity (LOH) was performed using MLPA (SALSA P244 probemix, MRC-Holland, The Netherlands).

2.4 | Microarray hybridization and data analysis

RNA samples were analyzed by the GeneChip miRNA 1.0 array (Affymetrix/Thermo Fisher Scientific), which is based on the Sanger miRBase miRNA database v11 (April 15, 2008). Tumor tissue was isolated from previously identified FFPE tissue sections with the RNeasy FFPE Kit (#73504, Qiagen). Total RNA (250 ng) was labeled with the FlashTag Biotin HSR kit (Genisphere) and hybridized. Staining and scanning were done according to the Affymetrix expression protocol. Array data was processed and annotated with the miRNA QC tool (Affymetrix, version 1.0.33.0) using settings recommended by Genisphere. Briefly, background was detected and removed by RMA global background correction, followed by quantile normalization and summarization using median polishing. Statistical analysis of the resulting dataset was performed by utilizing the statistical programming environment R (R Development Core Team 2011 R: A Language and Environment for Statistical Computing. Vienna, Austria: The R Foundation for Statistical Computing). Vienna, Austria: The R Foundation for Statistical Computing) implemented in CARMAweb.26 Genewise testing for differential expression was done employing the limma t-test and Benjamini-Hochberg multiple testing correction. All gene sets were filtered for true detection in at least half of the samples in at least one group per comparison. For technical replicates, the average was used for calculations. Functional annotations were generated through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, www.qiagen.com/ingenuity) using Fisher’s exact test P values. Input was regulated eight miRNAs from somatotropinomas (FC > 1.5x, P < .002; miR-383 was excluded). Heat maps were generated in R.

2.5 | Plasmid constructs and antibodies

The p.R271W mutation was introduced by site-directed mutagenesis (QuikChange II Site-Directed Mutagenesis Kit, #200523, Agilent Technologies) in the wild-type human AIP cDNA cloned in a pCMV-Myc backbone. The mutagenesis was verified by sequencing.

A fragment containing the predicted seed match and the mutated seed match of miR-34a in the rat 3’UTR of the GNAI2 gene was generated by annealing two oligos that represent the top and bottom
strand of the fragment. After oligo annealing, the fragments were cloned in a psiCHECK-2 backbone (#C8021, Promega).

Primers and Oligos for cloning and mutagenesis are listed in Table S2.

Primary antibodies are listed in Table S3.

### 2.6 Quantitative real-time polymerase chain reaction

RNA was extracted using RNeasy Kit (#74104, Qiagen) or with the Maxwell 16 LEV simplyRNA Purification Kit (#AS1270, Promega) following the manufacturer's instructions. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using TaqMan inventoried primers and probes (Applied Biosystems, Foster City, California) for the indicated genes, as described previously.  

The differential expression of selected miRNAs was validated by qRT-PCR. RNA was isolated using the miRNeasy Mini Kit (#217004, Qiagen) and miRNA concentration was determined as described before. Synthesis of cDNA was performed by TaqMan miRNA Reverse Transcription Kit (#4366596, Applied Biosystems) and primer sets for the respective miRNAs (Applied Biosystems). For qRT-PCR miRNA primer sets (Applied Biosystems) for the indicated miRNAs were used. All reactions were performed in triplicate PCR reactions with U6 snRNA (#4427975, Applied Biosystems) as an endogenous control using a comparative Ct method.

### 2.7 Cell culture and transient transfections

GH3 cells (RRID:CVCL 0273; Rattus norvegicus mixed GH-prolactin secreting PA cell line), MEFs from AIP knockout mice (MEF AIP −/−) (RRID:CVCL U02), HEK293 cells (RRID:CVCL 0045) and GH4C1 cells (RRID:CVCL 0276) clone of GH3 with little or no detectable levels of growth hormone were maintained in culture as described in Table S4. Cell lines were purchased by LGC Promochem, whereas AIP−/− MEFs were established in the laboratory of A. Karhu. All miRNA mimics used and inhibitors with respective controls are listed in Table S5.

MEF AIP −/− were transiently transfected with AIP plasmids and miRNA hairpin inhibitors (25 nM) with the 4D-Nucleofector System X unit (Lonza Group AG) and the P4 Primary Cell 4D-Nucleofector X Kit L (#V4XP-4012, Lonza Group AG). Electroporation was conducted using the pulse code CZ-167.

GH3 cells were transiently transfected with 150 nM miRNA mimics (miRIDIAN unspecific control mimic; miRIDIAN microRNA rat mno-miR-34a mimic; miRIDIAN microRNA rat mno-miR-145 mimic, from Dharmacon) or hairpin inhibitors (miRIDIAN microRNA rat mno-miR-34a inhibitor, from Dharmacon) using the 4D-Nucleofector System X unit and the SF Cell Line 4D-Nucleofector X Kit L (#V4XC-2012, Lonza Group AG). Electroporation was conducted using the pulse code DS-131.

HEK293 cells were authenticated within the last 3 years by DSMZ (Braunschweig) using short tandem repeat profiling. HEK293 cells were plated 24 hours before transfection in 24-well plates at a density of 0.05 × 10^5 cells per well. The cells were transiently transfected with Lipofectamine 3000 Transfection Reagent (#L3000015, Thermo Fisher Scientific Inc.) according to the manufacturer's instructions with 1 μg of the vector and 150 nM of either negative control inhibitor or anti-miR-34a.

All cell lines were routinely tested for mycoplasma contamination using the PCR Mycoplasma Test Kit (#PK-CA91-1048, PromoKine) and found to be mycoplasma-free.

### 2.8 Drug treatments

Cells were treated with 25 μg/mL cycloheximide (#C4859, Sigma-Aldrich) and 10 μM epoxomycin (EPOX, #BML-P127-0100, Enzo Life Sciences) in complete medium for the indicated times.

For therapy response, cells were treated with 10 or 100 nM octreotide (kindly provided by Italfarmaco SpA) in serum-free medium for the indicated times.

### 2.9 Protein extraction and Western blotting

Cells were collected at the indicated time points and lysed in radiometricprecipitation assay (RIPA) buffer (#R0278, Sigma-Aldrich) supplemented with protease (#04693124001, Roche Diagnostics) and phosphatase inhibitors (#04906845001, Roche Diagnostics). Protein concentrations were determined by the Pierce BCA Protein Assay Kit (#23225, Thermo Fisher Scientific Inc.). Equal protein amounts were separated on 10% SDS-PAGE gels. Antibodies were applied at 4°C overnight incubation (primary antibody) and 1-hour incubation (secondary antibody) at room temperature. Proteins were visualized by the SuperSignal West Pico Chemiluminescent Substrate Kit (#34080, Thermo Fisher Scientific Inc.).

### 2.10 Functional characterization of transfected cells

Cell viability was assessed by a colorimetric assay using Wst-1 reagent according to the manufacturer's recommendations (#11644807001, Roche, La Roche Ltd).

Migration assays were performed using 24-well plates with uncoated polycarbonate membrane inserts (#353097, BD Biosciences). Cells were allowed to migrate for 24 hours. Membranes were stained by 1.5% (w/v) Toluind Blue (#115930, Merck), fixed with Methanol (#106009, Merck) and mounted on glass slides with Pertex mounting medium (#41-4010-00, MEDITA GmbH). Images were recorded using an Olympus BX43 microscope.

Clonogenic potential of the cells was monitored by seeding the miRNA overexpressing cells at a low density of 1 × 10^3 cells per well in six-well plates. After 8 days, colonies were stained with 0.3% Crystal Violet in 30% ethanol and those with a diameter >100 μm were counted.
GH3 cells transfected with miRNA mimics were plated in 96-well plate at a density of 1.5 × 10^5 cells per well and six wells per group. For assessment of apoptosis in the cells, Caspase-Glo 3/7 Assay (#G8909, Promega) was performed according to the manufacturer’s instructions.

2.11 | Immunoassays

Transfected GH3 cells (7 × 10^5 per well) were plated in six-well plates and 24 hours later, cAMP levels were determined by using an ELISA kit (#ADI-900-006, Enzo Life Sciences) according to the manufacturer’s protocol. After transfection GH3 cells were plated at a density of 8 × 10^4 cells per well in a 24-well plate in serum-free medium. After 24 hours, cells were treated with 100 nM Octreotide for additional 48 hours. The supernatant was then collected and GH was measured using a Rat/Mouse ELISA Kit (#EZRMGH-45K, Merck Millipore) whereas prolactin was measured with the rat ELISA Kit (#S89701, Cayman Chemical).

2.12 | miRNA target prediction

The targets of the differentially expressed miRNAs were predicted by four different prediction tools, TargetScan 7.0, miRANNA-mirSVR, DIANA tools and PITA that take different parameters into consideration (Table S6).

2.13 | Reporter gene assays

To conduct reporter gene assays, HEK293 cells were lysed 24 hours after transfection according to the protocol of the Dual-Luciferase Reporter (DLR) Assay Kit (#E1980, Promega). Subsequently the reporter assay was performed according to the manufacturer’s instructions.

2.14 | Immunohistochemistry and scoring

Immunohistochemical stainings were performed on an automated immunostainer (Ventana Medical Systems) as previously described. Primary antibodies were diluted in Dako REALTM antibody diluent (Dako). Positive controls were included in each run. The slides were counterstained with hematoxylin for 10 seconds and washed under running water for 4 minutes. Images were recorded using an Olympus BX43 microscope (Olympus). For Gαι-2-immunohistochemistry (IHC) an Avidin-Biotin block (AB-block) was used to decrease unspecific background staining. For AIP-IHC the AB-block was not necessary. IHC results were evaluated using a semiquantitative method that assessed the staining intensity: − (negative), + (mild), ++ (moderate) and +++ (strong). Slides were scored using a double-blind method by two independent observers; the percentage of discrepancies was below 3%. Images were recorded using a Hitachi camera HW/C20 installed in a Zeiss Axioplan microscope with Intellicam software (Carl Zeiss Microlmaging).

2.15 | Statistical analysis

Results of the cell assays are shown as the mean of values obtained in independent experiments ± SEM. Unpaired two-tailed Student’s t-test, Mann-Whitney test, one-way and two-way ANOVA were used to detect significance between two series of data, and P < .05 was considered statistically significant.

3 | RESULTS

3.1 | miRNA expression analysis in AIPmut+ vs AIPmut– adenomas

Eighteen PAs were used for miRNA profiling (Figure S2) using GeneChip miRNA arrays. In somatotropinomas, nine miRNAs were differentially expressed (P < .002) in AIPmut+ compared to AIPmut– tumors and showed a >1.5-fold change in expression. Six of them (miR-187, miR-383, miR-145, miR-34a, miR-143, miR-1231) were significantly upregulated and three (miR-195, miR-497, miR-26a) downregulated in AIPmut+ vs AIPmut– (Figure 1A). In prolactinomas, three miRNAs were regulated using the same criteria (Figure S3). One AIPmut+ prolactinoma was excluded due to suboptimal RNA quality, and since only two samples remained, we focused on the somatotropinomas for subsequent analyses. Some of the significant differentially expressed miRNAs have previously been linked to PAs, including miR-26a, downregulated in prolactinomas vs normal pituitary and upregulated in invasive adenomas; miR-143 and miR-145 were downregulated in ACTH-secreting adenomas vs normal pituitary, and miR-383, downregulated in invasive NFPAs. To obtain a functional annotation of the differentially expressed miRNAs, we used Ingenuity Pathway Analysis. The most enriched terms were cancer-related, followed by terms related to cellular cycle and cell movement (Table S7), further supporting a role for the differentially expressed miRNAs in tumors. To validate the miRNA array results, we assessed the miRNAs with the highest differential expression (ie, miR-187, miR-383, miR-145, miR-34a and miR-195) by quantitative qRT-PCR in somatotropinoma samples. These analyses confirmed a significant upregulation of miR-187, miR-145 and miR-34a and a downregulation of miR-195 in AIPmut+ vs AIPmut– somatotropinomas (Figure 1B-F), whereas the differential expression of miR-383 could not be validated.

3.2 | Effects of mutant AIP in MEFs of Aip<sup>+/−</sup> mice

Given that the AIP-R271W mutation was predominant in our cohort (and is the most frequent missense AIPmut reported) we focused on
FIGURE 1  Legend on next page.
this mutated AIP protein. We first determined whether ectopic expression of the AIP-R271W variant affects cell proliferation. To avoid interference from endogenous wild-type AIP, MEFs from Aip<sup>−/−</sup> mice were transfected with AIP wild-type (wt) or AIP-R271W and cell proliferation was measured 24, 48 and 72 hours later. At the 24 hours time point, AIP-R271W increased cell proliferation vs AIP-wt (Figure 1G). This effect was no longer present 48 hours after transfection (Figure 1G). Western blot analysis revealed that the AIP-R271W protein was detectable only up to 24 hours after transfection, while AIP-wt was present throughout the duration of the experiment, suggesting that mutant AIP is less stable. Treatment of transfected cells with cycloheximide (CHX) confirmed this hypothesis: while AIP-wt showed no decrease up to 20 hours post-transfection, the level of AIP-R271W started to decrease already after 4 hours (Figure S4A). Treatment of transfected MEFs with both CHX and the proteasome inhibitor epoxomycin (EPOX) established that the degradation of mutant AIP is mediated, at least in part, by the proteasome (Figure S4B). This is in agreement with previously reported in vitro data analyzing the half-life of various AIPmut, including R271W. Therefore, all subsequent experiments were conducted 24 hours after transfection and plasmid DNA was adjusted to reach equal protein levels for AIP-wt and AIP-R271W. Taken together, the ectopic expression of AIP-R271W promoted the proliferation of Aip<sup>−/−</sup> MEFs despite being present at low levels.

### 3.3 Regulation of miRNA expression by mutant AIP in Aip<sup>−/−</sup> MEFs

To demonstrate a direct link between the presence of mutant AIP and differential miRNA expression, Aip<sup>−/−</sup> MEFs were transiently transfected with AIP-wt or AIP-R271W and the levels of selected differentially expressed miRNAs were assessed by qRT-PCR. In line with the array analyses, miR-34a and miR-145 were upregulated upon transfection of AIP-R271W vs AIP-wt (Figure 1H). In contrast, the level of expression of miR-195 and miR-187 was similar in both conditions (Figure 1J). Thus, miR-34a and miR-145 were chosen for further in vitro characterization.

### 3.4 Short-term upregulation of miR-145 and miR-34a promotes oncogenic features in PA cells

We next investigated whether upregulation of miR-34a and/or miR-145 (mimicking AIPmut+ tumors) affects the phenotypic features of PA cells. GH3 cells (derived from a rat GH/prolactin-secreting adenoma) were transfected with specific mimics for mature miR-34a and miR-145, and functional assays were performed assessing proliferation, clonogenic potential, migration and apoptosis (Figure 2A-D). Short-term overexpression of both miRNA mimics (24 hours) increased GH3 cell proliferation when compared to cells transfected with an unspecific control miRNA mimic (Figure 2A). GH3 cells overexpressing miR-34a migrated significantly more than the control ones, whereas transfection of miR-145 mimic had no effect on cell migration (Figure 2B). miR-34a and miR-145 overexpression decreased GH3 cells apoptosis, with miR-34a having the stronger effect (Figure 2D). miR-34a, but not miR-145, upregulation increased by 2-fold the clonogenic potential of GH3 cells vs cells transfected with unspecific miRNA control (Figure 2C). Altogether, high levels of miR-34a increased proliferation, clonogenicity, migration and suppressed apoptosis of PA cells. miR-145 upregulation only moderately promoted proliferation and decreased apoptosis.

#### 3.5 miR-34a but not miR-145 overexpression impairs the response to octreotide

Acromegaly and gigantism patients carrying AIP mutations poorly respond to somatostatin receptor subtype 2 (SSTR2)-specific SSAs such as octreotide and lanreotide; consequently, GH normalization and tumor shrinkage are limited in AIPmut+ -related acromegaly when compared to AIPmut− patients. Given that mutated AIP upregulates miR-34a and miR-145, we assessed whether the levels of these miRNAs affect the ability of PA cells to respond to octreotide. GH3 cells were transfected with miRNA mimics as above, treated with octreotide for 72 hours and then cell proliferation was measured. Cells overexpressing the unspecific miRNA control and treated with octreotide showed decreased proliferation (~37%) vs untreated cells (Figure 2E), as previously reported. A comparable reduction in cell proliferation was also observed in cells overexpressing miR-145 and treated with octreotide (~49%), whereas no suppression of cell proliferation was detected upon miR-34a upregulation (Figure 2E). This suggests that high miR-34a levels abolished the octreotide-dependent inhibition of PA cell proliferation.

Octreotide suppresses GH and prolactin (PRL) secretion from GH3 cells in vitro. Overexpression of AIP-wt in GH3 cells reduces GH secretion by decreasing cAMP levels. Thus, we measured GH in the supernatant of GH3 cells transfected with the above miRNA.
FIGURE 2  Legend on next page.
mimics and treated with octreotide for 48 hours (Figure 2F). For sake of completeness, we also measured PRL levels in the cells supernatant (Figure 2G). As expected, octreotide incubation led to a significant decrease in both GH and PRL secretion in cells transfected with the unspecific miRNA control (Figure 2F,G). A similar result was obtained in cells overexpressing miR-145 (~44% and ~22%, respectively; Figure 2F,G). In contrast, upregulation of miR-34a led to a loss of octreotide-mediated suppression of both GH and PRL secretion (Figure 2F,G), indicating that high miR-34a levels mediated the lack of response of GH3 cells to octreotide treatment.

3.6 Effects of the validated miRNAs on cAMP signaling in PA cells

Increased cAMP levels are an important hallmark of neuroendocrine tumors including PAs. Moreover, cAMP signaling is dysregulated following AIP inactivation in mice and this associated with somatotrope tumorigenesis. Therefore, we measured cAMP levels in GH3 cells transfected with miR-145 or miR-34a mimics, or with an unspecific miRNA control. Overexpression of miR-34a almost doubled the intracellular levels of cAMP in GH3 cells when compared to cells transfected with the unspecific negative control, whereas ectopic miR-145 expression had no effect on the amount of cAMP (Figure 2G).

cAMP has been reported to exert its mitogenic effect in somatotroph cells via phosphorylation of extracellular signal-regulated kinases (ERK1/2). Therefore, we assessed total and phosphorylated ERK1/2 by western blotting. Overexpression of both miR-34a and miR-145 increased the levels of phosphorylated ERK1/2 compared to both untransfected and unspecific control-transfected cells (Figure 2H,I). The increase in phospho-ERK1/2 was more pronounced following miR-34a overexpression (vs miR-145) and this paralleled the higher intracellular levels of cAMP (Figure 2G).

3.7 Guanine nucleotide-binding protein G(1) subunit alpha-2 (GNAI2) as a novel predicted target gene of miR-34a

AIPmut in PAs leads to upregulation of miR-34a, which in turn promotes proliferation and cAMP signaling. To better understand these effects, we identified predicted miR34a target genes using four different prediction tools (Table S6). Following the criteria outlined above, we selected several putative target genes (Table S8). As TargetScan considers only seed match and conservation for target prediction (Table S6), we excluded targets predicted only by algorithm alone. We focused on genes involved in cAMP signaling (Table S9), which included several phosphodiesterases (PDE3a, PDE4A, PDE5a, PDE7b) and G-protein alpha subunit family members (GNAO1, GNAI2, GNAI3, GNAQ; Table S9). GNAI2 and GNAI3 are interesting candidates as they encode inhibitory Gs subunits which lead to decreased cAMP levels. To verify whether these genes were regulated by miR-34a, we transfected GH3 cells with the miR-34a mimic (for overexpression) or a specific anti-miR-34a (for downregulation) and assessed the level of GNAI2 and GNAI3. The modulation of miR-34a levels were confirmed by qRT-PCR at 24 hours and 48 hours post-transfection (Figure S5). AIP was previously shown to be regulated by miR-34a and was thus included (Figure 3A,B). miR-34a overexpression decreased Gna2 mRNA levels by about 30% vs nonspecific miRNA negative control transfected cells (Figure 3B); miR-34a downregulation increased Gna2 expression by about 1.5-fold (Figure 3E). No changes in Gna3 levels were observed after miR-34a modulation (Figure 3C,F).

Then, we tested whether miR-34a directly targets Gna2 using reporter gene assays. Given that a seed match for miR-34a in the 3′UTR region of rat Gna2 was predicted, we cloned this sequence into the psiCHECK-2 vector upstream of the firefly luciferase gene (Figure 3G). This construct was then transfected into HEK293 cells.
together with an unspecific miRNA inhibitor or the anti-miR-34a, and luciferase activity was monitored. A decrease in luciferase activity was detected between cells cotransfected with empty vector and unspecific control miRNA inhibitor vs cells cotransfected with empty vector and anti-miR-34a inhibitor (Figure 3I). In contrast, anti-miR-34a increased the luciferase activity of the construct containing the Gnai2
3.8 | Gu2i2 expression is reduced in human AIPmut + PAs

AIPmut+ PAs show an increase in miR-34a expression, which in turn regulates Gu2i2 expression. Thus, we next investigated Gu2i2 (and AIP) expression by immunohistochemistry (IHC) on AIPmut– and AIPmut+ samples (Table S1). Slides were then scored semiquantitatively for staining intensity (Figure 4A). In total, 38 human PA tumors were scored for AIP expression and 30 (n = 18 AIPmut–; n = 12 AIPmut+) for Gu2i2 expression (Figure 4B,C). We found that levels of Gu2i2 were significantly lower in AIPmut+ vs AIPmut– tumors (P < .05; Figure 4D), whereas there was no statistically significant difference in AIP staining between the two sample groups (Figure 4E). By only considering the somatotropinomas (n = 13, AIPmut–; n = 9, AIPmut+), decreased Gu2i2 staining in AIPmut+ tumors was even more pronounced (P < .01; Figure 4F). Again, no significant difference in AIP expression was detected between AIPmut+ and AIPmut– somatotropinomas (Figure 4G). Not always tumors of AIPmut+ patients lacked AIP expression (Figure S6). A positive correlation between Gu2i2 and AIP was found when all samples (AIPmut+ and AIPmut–) were analyzed together (Figure S7A). A detailed analysis of each group revealed that the positive correlation could only be observed in AIPmut– (Figure S7B), but not in AIPmut+ (Figure S7C) samples.

In AIPmut– PAs, invasive tumors have a lower expression score of both, AIP and Gu2i2 (Figure S7A,C), whereas no difference in expression scores of either protein was seen in the AIPmut+ patient group (Figure S8).

4 | DISCUSSION

Acromegaly is a rare and disfiguring disease that, if inadequately treated, carries significant morbidity and increased mortality.12 Resistance to medical therapy with SST2-specific SSAs like octreotide or lanreotide is an important impediment to hormonal control in acromegaly. AIPmut in acromegaly leads to such SSA resistance, which has a major clinical impact on patients as AIPmut are also associated with young-onset, large and invasive PAs.10 The mechanisms to explain this phenotype are therefore of high clinical relevance. We report here for the first time that AIPmut+ somatotropinomas have a distinct miRNA profile of miR-34a upregulation, a well-known miRNA that can function as an oncomiR in multiple cancers. Loss of AIP due to mutation led to increased miR-34a, which was associated with increased cAMP and low Gu2i2 expression. Importantly, miR-34a dysregulation also recapitulated the SSA-resistant phenotype of human AIPmut, with blunting of the antiproliferative and GH secretory effects of octreotide. This suggests that the aggressive and therapeutically-resistant features of AIPmut in PA could be mediated by dysregulated miR-34a.

Nine miRNAs were differentially expressed between AIPmut+ and AIPmut– somatotropinomas, five of which were validated by qRT-PCR: miR-187, miR-145, miR-34a, (upregulated in AIPmut+) and miR-195 (downregulated). Among the AIPmut+ PA samples we used, the nonsense mutation p.R271W was the most frequent and is a recurrent mutation clinically.38 As p.R271W is known to affect AIP function,37 we used this variant to verify the causal relationship between mutant AIP and miRNA expression by ectopically over-expressing AIP-R271W in Aip-deficient MEFs. AIP-R271W was present at much lower levels than wild-type AIP due to enhanced degradation in part through the proteasome. This accords with Hernandez-Ramirez et al who reported decreased stability of AIP-R271W in HEK293 cells.30 Despite its short half-life, ectopic AIP-R271W promoted AIP−/− MEFs proliferation. This effect was accompanied by specific upregulation of miR-34a and miR-145, thereby establishing a relationship between AIPmut and expression of these two miRNAs.

In rat pituitary GH3 cells, upregulation of miR-34a promoted migration and inhibited apoptosis, whereas miR-145 moderately increased cell viability and decreased apoptosis. Furthermore, octreotide inhibited proliferation and GH secretion in GH3 cells, whereas, miR-34a overexpression counteracted this. Therefore, stimulation of miR-34a expression by mutant AIP leads to resistance to

FIGURE 3 | miR-34a directly targets Gna12 in GH3 cells. GH3 cells were just pulsed without DNA, or transfected with an unspecific miRNA (unspecific control), with a specific mimic for mature miR-34a (A–C) or with an antagonist of miR-34a (D–F). mRNA levels of Aip (A, D), Gna12 (B, E), or Gna13 (C, F) were determined 24 hours after transfection by qRT-PCR. Each amplification was independently performed 3 to 6 times each with two technical replicates. The values are normalized against the unspecific control arbitrarily set to 100%. Results are reported as the mean ± SEM. ***P < .001; n.s., not significant (by one-way ANOVA). G, Sequence of the DNA fragment cloned into the psiCHECK-2 luciferase vector (Gna12 oligos) which contains the predicted seed match of miR-34a (pink) located in the 3′ UTR of the rat Gna12 gene (yellow). H, Sequence of the DNA fragment cloned into the psiCHECK-2 luciferase vector (Gna12 oligos) which contains a deletion of the predicted seed match of miR-34a (pink) in the 3′ UTR of the rat Gna12 gene (yellow). I, HEK293 cells were co-transfected with the empty vector and an unspecific miRNA inhibitor (unspecific control inhibitor) or a specific antagonist for miR-34a (anti-miR34a), with the seed match-containing vector (shown in a) and either the unspecific miRNA or the specific anti-miR34a or with the mutated seed match-containing vector (shown in b) with the unspecific miRNA or the specific anti-miR34a. The experiment was independently performed three times each with three technical replicates. The values are normalized against an untransfected control (not shown in the graph). Results are reported as the mean ± SEM. **P < .01; ***P < .001; n.s., not significant (by two-way ANOVA). UT, untransfected; UT Nuc, untransfected Nucleofector; UC, unspecific control; ev, empty vector; sm, seed match; mut sm, mutated seed match.
FIGURE 4  

Gαi2 expression levels are reduced in human AIPmut + PAs. A, Immunohistochemical staining of four representative primary PAs for Gαi2 and AIP. The samples cover the range of staining intensities observed (0; +; ++; +++). Antibodies anti-Gαi2 (1/200) and anti-AIP (1/1000) were used. Original magnification: x200; scale bar = 20 μm. B,C, Staining intensities of the samples that could be scored for Gαi2 (B, n = 30) or AIP (C, n = 38). Samples are divided in AIPmut− and AIPmut+ PAs. Expression of AIP and Gαi2 in human AIPmut− and AIPmut+ PAs. D−E, Gαi2 (D) and AIP (E) staining intensities in AIPmut− and AIPmut+ samples. F−G, Gαi2 (F) and AIP (G) staining intensities in AIPmut− and AIPmut+ somatotropinomas. Results are reported as the mean ± SEM. *P < .05; **P < .01; n.s., not significant (by unpaired two-tailed Student's t-test)
octreotide treatment, thereby recapitulating the clinical phenotype of AIPmut+ PA patients.

Both miR-34a and miR-145 have been implicated in various human tumors. miR-145 is co-transcribed with miR-143 and both have been described as a tumor suppressive miRNAs in corticotropinomas and craniopharyngioma. In PAs, mir-145 inhibits mTOR signaling in invasive tumors, sensitizes prolactinoma cells to bromocriptine, is downregulated in invasive NFPAs and its overexpression reduces proliferation and invasion of NFPA cells in vitro. miR-145 can, however, also foster tumor development: knockout of the miR-143/miR-145 cluster reduced tumor number and tumor area, and increased angiogenesis in a lung cancer mouse model.

miR-34a, together with miR-34b and miR-34c, are transcriptionally regulated by p53. miR-34a was initially considered a tumor suppressor since it is downregulated in several cancers, and reduces proliferation and induces apoptosis of tumor cells. However, recent evidence also points to a pro-oncogenic role for miR-34a as it is overexpressed in gastric cancer and brain tumors, among others. miR-34a plays a proproliferative and antiapoptotic role in vascular and lymphoid tissues, and it was also found to induce chemoresistance of osteosarcoma cells, and to promote genomic instability. Therefore, miR-34a overexpression, a feature often acquired during carcinogenesis, can play an oncogenic or tumor-suppressive role in a tissue- and context-specific manner. In the normal pituitary, miR-34a is expressed at a level similar to that seen in AIPmut+ somatotropinomas, being overexpressed only in adenomas with an AIP mutation (Figure S9). Interestingly, miR-34a was previously shown to have increased expression in non-AIPmut somatotropinomas with low AIP protein levels, and to directly target and inhibit AIP in a nonpituitary model (HEK293). While Denes et al. found only a modest effect of increased miR-34a on Aip protein levels in GH3 cells, we have expanded this to show that AIPmut in PAs specifically upregulates miR-34a, where it functions as an oncomiR.

In contrast to findings from our group and from Denes et al., it was recently reported that long-term overexpression of miR-34a decreases the proliferation of GH4C1 cells, a clone derived from GH3 cells but that produces negligible amounts of GH. We did not see changes in GH4C1 cell proliferation upon overexpression of miR-34a up to 72 hours posttransfection (Figure S10) whereas in GH3 cells an increase in viability was already detectable 24 hours post-transfection and lasted for several days (eg, in clonogenic assays). This discrepancy suggests that miR-34a elicits different effects due to underlying secretory and molecular heterogeneity between GH3 and GH4C1 clones.

Dysregulation of intracellular cAMP levels is a hallmark of functioning endocrine tumors, including somatotropinomas, where cAMP promotes cell division and GH secretion. A link between AIP and cAMP has been established in that overexpression of wild-type AIP in GH3 cells attenuates the forskolin-dependent increase in intracellular cAMP and GH secretion, whereas silencing of endogenous Aip increases cAMP concentration. Mechanistically, AIP interacts with several members of the cAMP signaling cascade, including phosphodiesterases, the enzymes that deactivate cAMP, and G proteins, which can either activate AC and increase cAMP (activating) or have the opposite effects (inhibitory). In Aip-deficient MEFs, the inhibitory Gαι2 and Gαι3 proteins do not inhibit cAMP synthesis, which suggests that AIPmut-related pituitary tumorigenesis may occur via Gαι signaling and cAMP. In this context, our finding that in PA cells AIPmut leads to upregulation of miR-34a, which in turn increases intracellular cAMP levels, offers an additional molecular mechanism relating defective AIP to cAMP production (Figure 5). Among the predicted miR-34a

![Diagram](image-url)
targets was GNAI2 encoding Gαi2, which was confirmed to be a direct target by reporter gene assays. Accordingly, miR-34a overexpression in PA cells reduces GNAI2 levels, while its downregulation increases them. A reduction intracellular levels of Gαi2 is expected to enhance AC activity and to increase cAMP levels, which we observed. Although a role has been suggested for Gαi2 in mediating the effects of defective Aip, the mechanism was unknown as loss-of-function mutations in GNAI genes are not seen in PAs.58 We demonstrate that AIPmut decreases GNAI2 expression via miR-34a-3p, and this ultimately leads to increased AC activity as well as cAMP levels (Figure 5).

In line with previous reports, we observed a trend towards a negative correlation between AIP levels and tumor size.59,60 Also, we confirmed that low AIP staining is associated with higher likelihood of tumor invasion and AIPmut+ status did not predict AIP staining intensity.61 We also found that AIPmut are associated with a reduction in Gαi2 levels, thereby extending the findings of Tuominen et al.17 Similar to AIP, the levels of Gαi2 are reduced in invasive vs noninvasive PAs only in the AIPmut+ group.

In summary, we show that AIPmut in GH-secreting PAs leads to dysregulation of a specific subset of miRNAs, including miR-34a, which is induced by AIPmut and has pro-oncogenic functions in somatotropinomas through regulation of Gαi2 expression and increased cAMP concentrations. As increased levels of miR-34a impair the response of PA cells to octreotide, the lack of response of AIPmut+ patients to first-generation SSAs might be mediated by induction of miR-34a expression. These findings further support the hypothesis that failure to inhibit cAMP synthesis due to down-regulation of Gαi2 is a key event in AIP-mediated pituitary tumorigenesis. Furthermore, this adds another level of complication to the multifaceted role of AIP in PAs given that the increase of miR-34a may lead to the regulation of other genes in addition to Gαi2. As both high miR-34a and low Gαi2 levels are associated with resistance to SSA therapy, they represent potential biomarkers that could be used as evidence to personalize treatment choices and improve outcomes in AIPmut patients.

ACKNOWLEDGEMENTS
The authors thank E. Pulz for excellent technical assistance; Dr S. Molatore for advice and Prof. S. Herzig for scientific support. We thank the patients whose participation made our study possible. This work was supported by the Deutsche Forschungsgemeinschaft (DFG) within the CRC/Transregio 205/1 (subproject B11), by the Deutsche Krebshilfe (grant 70112383), by the Fonds d’Investissement Pour la Recherche Scientifique (FIRS) 2014-2018, CHU de Liège and by a grant from the JABBS Foundation, UK. This work was partially supported by the Helmholtz Alliance “Aging and Metabolic Programming, AMPro” (to J. B.). Open access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTEREST
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

DATA AVAILABILITY STATEMENT
The array data are openly available in GEO (GSE140604). All other data will be made available upon reasonable request.

ETHICS STATEMENT
These studies were approved by the local ethics committees and prior to surgery, all patients signed a written informed consent.

ORCID
Natalia S. Pellegrato https://orcid.org/0000-0002-8000-7784

REFERENCES
1. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol. 2018;20:iv1-iv86.
2. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liège, Belgium. J Clin Endocrinol Metab. 2006; 91:4769-4775.
3. Casanueva FF, Barkan AL, Buchfelder M, et al. Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement. Pituitary. 2017;20:489-498.
4. Daly AF, Beckers A. Chapter 21—genes of pituitary tumor syndromes. The Pituitary. Amsterdam: Elsevier; 2017:619-630.
5. Daly AF, Jaffrain-Rea M-L, Ciccarelli A, et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab. 2006; 91:3316-3323.
6. Trivellin G, Daly AF, Fauz FR, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014; 371:2363-2374.
7. Wise-Oringer BK, Zanazzi GJ, Gordon RJ, et al. Familial X-linked Acrogigantism: postnatal outcomes and tumor pathology in a prenatally diagnosed infant and his mother. J Clin Endocrinol Metab. 2019; 104:4667-4675.
8. Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science (80-.). 2006;312:1228-1230.
9. Daly AF, Vanbellinghen J-F, Sok KK, et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab. 2007;92:1891-1896.
10. Daly AF, Tichomirowa MA, Petroossians P, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95:E373-E383.
11. Buchfelder M, Schlaffer S. The surgical treatment of acromegaly. Pituitary. 2017;20:76-83.
12. Katznelson L, Laws ER, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99: 3933-3951.
13. Fuentes-Fayos AC, Garcia-Martinez A, Herrera-Martinez AD, et al. Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. Minerva Endocrinol. 2019;44:109-128.
14. Igure S, Chahal HS, King P, et al. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat. 2010;31:950-960.
15. Schernthaner-Reiter MH, Trivellin G, Stratakis CA. Interaction of AIP with protein kinase a (cAMP-dependent protein kinase). Hum Mol Genet. 2018;27:2604-2613.
16. Bolger GB, Bizzi MF, Pinheiro SV, et al. cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors. Endocr Relat Cancer. 2016;23:419-431.
17. Tuoimen I, Hellövaa E, Raitila A, et al. AIP inactivation leads to pituitary tumorigenesis through defective Gui-cAMP signaling. Oncogene. 2015;34:1174-1184.

18. Ritvonen E, Pitkänen E, Karppinen A, et al. Impact of AIP and inhibitory G protein alpha 2 proteins on clinical features of sporadic GH-secreting pituitary adenomas. Eur J Endocrinol. 2017;176:243-252.

19. Bottani A, Zatelli MC, Ferracin M, et al. Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. J Cell Physiol. 2007;213:370-377.

20. Bottani A, Piccin D, Tagliati F, Luchin A, Zatelli MC, degli Uberti EC. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol. 2005;204:280-285.

21. Butz H, Liko I, Czirjak S, et al. MicroRNA profile indicates down-regulation of the TGFβ pathway in sporadic non-functioning pituitary adenomas. Pituitary. 2011;14:112-124.

22. Amaral FC, Torres N, Saggio F, et al. MicroRNAs differentially expressed in ACHT-secreting pituitary tumors. J Clin Endocrinol Metab. 2009;94:320-323.

23. Jian M, Du Q, Zhu D, et al. Tumor suppressor miR-26a and pleomorphic adenoma gene 1 (PLAG1) in invasion patterns with human pheochromocytoma. J Cell Physiol. 2016;231:5101-5108.

24. Molatore S, Liyanarachchi S, Irmler M, et al. Pheochromocytoma in expressed microRNAs by microarray: a possible role for microRNA expression in sporadic somatotropinomas. J Endocrinol. 2005;204:280-285.

25. Molatore S, Liyanarachchi S, Irmler M, et al. Pheochromocytoma in expressed microRNAs by microarray: a possible role for microRNA expression in sporadic somatotropinomas. J Endocrinol. 2005;204:280-285.

26. Rainer J, Sanchez-Cabo F, Stocker G, Sturm A, Trajanoski Z. CARMAweb: comprehensive R- and bioconductor-based web service for microarray data analysis. Nucleic Acids Res. 2006;34:W498-W503.

27. Molatore S, Liyanarachchi S, Irmler M, et al. Pheochromocytoma in expressed microRNAs by microarray: a possible role for microRNA expression in sporadic somatotropinomas. J Endocrinol. 2005;204:280-285.

28. Molatore S, Liyanarachchi S, Irmler M, et al. Pheochromocytoma in expressed microRNAs by microarray: a possible role for microRNA expression in sporadic somatotropinomas. J Endocrinol. 2005;204:280-285.

29. Hernández-Ramírez LC, Martucci F, Morgan RML, et al. Rapid proteasomal degradation of mutant proteins is the primary mechanism leading to tumorigenesis in patients with missense AIP mutations. J Clin Endocrinol Metab. 2016;101:3144-3154.

30. Cheung NW, Boyages SC. Somatostatin-14 and its analog octreotide exert a cytosstatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block. Endocrinology. 1995;136:4174-4181.

31. Grusza A, Ren S-G, Dong J, Culler MD, Melmed S. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology. 2007;148:6107-6114.

32. Formosa R, Xuereb-Anastasi A, Vassallo J. AIP regulates cAMP signaling and growth hormone secretion in GH3 cells. Endocrine-Related. 2013:20:495-505.

33. Vallar L, Spada G, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature. 1987;330:566-568.

34. Lania A, Filopanti M, Corbetta S, et al. Effects of hypothalamic neuropeptides on extracellular signal-regulated kinase (ERK1 and ERK2) cascade in human tumoral pituitary cells. J Clin Endocrinol Metab. 2003;88:1692-1696.

35. Pertuit M, Barlier A, Enjalbert A, Gérard C. Signalling pathway alterations in pituitary adenomas: involvement of Gsalpha, cAMP and mitogen-activated protein kinases. J Neuroendocrinol. 2009;21:869-877.

36. Dénes J, Kasuki L, Trivellini G, et al. Regulation ofaryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas. PLoS One. 2015;10:e0117107.

37. Bell DR, Poland A. Binding of aryl hydrocarbon receptor (AhR) to AhR-interacting protein. The role of hsp90. J Biol Chem. 2000;275:36407-36414.

38. Campanini ML, Colli LM, Paixao BM, et al. CTNNB1 gene mutations, pituitary transcription factors, and MicroRNA expression involvement in the pathogenesis of adamaninomatous craniohypygangiomas. Horm Cancer. 2010;1:187-196.

39. Zhou K, Fan YD, Wu PF, et al. MicroRNA-145 inhibits the activation of the mTOR signaling pathway to suppress the proliferation and invasion of invasive pituitary adenoma cells by targeting AKT3 in vivo and in vitro. Onco Targets Ther. 2017;10:1625-1635.

40. Du Q, Hu B, Feng Y, et al. circOMA1-mediated miR-145-5p suppresses tumor growth of nonfunctioning pituitary adenomas by targeting TPT1. J Clin Endocrinol Metab. 2019;104:2419-2434.

41. Dimitrova N, Gocheva V, Bhutkar A, et al. Stromal expression of miR-143/145 promotes Neoangiogenesis in lung cancer development. Cancer Discov. 2016;6:188-201.

42. Wang JX, Zhang QJ, Pei SG, Yang BL. Effect and mechanism of miR-34a on proliferation, apoptosis and invasion of laryngeal carcinoma cells. Asian Pac J Trop Med. 2016;9:494-498.

43. Deng X, Zheng H, Li D, et al. MicroRNA-34A regulates proliferation and apoptosis of gastric cancer cells by targeting silent information regulator 1. Exp Ther Med. 2018;15:3705-3714.

44. Braoudaki M, Lambrou GI, Giamnikiou K, et al. MicroRNA expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms. J Hematol Oncol. 2014;7:96.

45. Ruiz Espanza-Garrido R, Velazquez-Flores MA, Diegoperez-Ramirez J, et al. A proteomic approach of pediatric astrocytomas: MiRNAs and network insight. J Proteomics. 2013;94:162-175.

46. Ferretti E, De Smale E, Po A, et al. MicroRNA profiling in human medulloblastoma. Int J Cancer. 2009;124:568-577.

47. Wang P, Xu J, Hou Z, et al. miRNA-34a promotes proliferation of human pulmonary artery smooth muscle cells by targeting PDGFRA. Cell Prolif. 2016;49:484-493.

48. Sotillo E, Laver T, Mellert H, et al. Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene. 2011;30:2587-2594.

49. Rizzo M, Mariani L, Cavallini S, Simili M, Rainaldii G. The overexpression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation. Nucleic Acid Ther. 2012;22:283-288.

50. Pu Y, Zhao F, Li Y, et al. The miR-34a-5p promotes the multi-chemosensitivity of osteosarcoma via repression of the AGTR1 gene. BMC Cancer. 2017;17:45.

51. Krause CJ, Popp O, Thirunarayanan N, Dittmar G, Lipp M, Muller G. MicroRNA-34a promotes genomic instability by a broad suppression of genome maintenance mechanisms downstream of the oncogene KSHV-VGPRC. Oncotarget. 2016;7:10414-10432.

52. Yang Z, Zhang T, Wang Q, Gao H. Overexpression of microRNA-34a attenuates proliferation and induces apoptosis in pituitary adenoma cells via SOX7. Mol Ther Oncolytics. 2018;10:40-47.

53. Castillo AI, Aranda A. Differential regulation of pituitary-specific gene expression by insulin-like growth factor 1 in rat pituitary GH4C1 and GH3 cells”. Endocrinology. 1997;138:5442-5451.
56. Tagliati F, Gagliano T, Gentilin E, et al. Magmas overexpression inhibits staurosporine induced apoptosis in rat pituitary adenoma cell lines. PLoS One. 2013;8:e75194.
57. de Oliveira SK, Hoffmeister M, Gambaryan S, Muller-Esterl W, Guimaraes JA, Smolenski AP. Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. J Biol Chem. 2007;282:13656-13663.
58. Demir H, Donner I, Kivipelto L, et al. Mutation analysis of inhibitory guanine nucleotide binding protein alpha (GNAl) loci in young and familial pituitary adenomas. PloS One. 2014;9:e109897.
59. Kasuki Jomori de Pinho L, Vieira Neto L, Armondi Wildemberg LE, et al. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology. 2011;94:39-48.
60. Daly AF, Cano DA, Venegas-Moreno E, et al. Aip and men1 mutations and aip immunohistochemistry in pituitary adenomas in a tertiary referral center. Endocr Connect. 2019;8:338-348.
61. Jaffrain-Rea M-L, Angelini M, Gargano D, et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer. 2009;16:1029-1043.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Bogner E-M, Daly AF, Gulde S, et al. miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance. Int. J. Cancer. 2020;147:3523–3538. https://doi.org/10.1002/ijc.33268